Hey@ChocolateTeapot, indeed I have revised my spreadsheet model - for those that are interested LTR's KV 13 Yr Outlook - as always, feel free to download a copy and make your own assumptions. @Goldilocks, appreciate going through it in details and picking up the little things.
There are a few new addition/assumptions I've made:
1. The obvious one; increased in Capex to $895m (this I understood excludes Corporate, Working Capital and buffer); the estimated shortfall is at least $400m (could be more or less depending on what the revised working capital requirement, etc will be) - it's may seem significant at first; but if you consider the 2nd point below - this will likely be not the case and perhaps make it even more attractive.
2. Included 2024 FY for the DSO; as many have already pointed out - this is a material change to the bottom line pre-production; the DSO is not part of DFS reserves which would otherwise be just waste rock; cost/t at this point is unknown - we'll wait for future announcement to get a better grasp on the cost. However, if you look solely at the Gross Revenue the DSO could potential provide (see below; I took a mid-point between 850 Kt and 1200 Kt) - it could easily cover or pay off the additional funding we require - the best outcome (unlikely IMO) would be to fast-track DSO sales (incl. prepayment at discounted price/t) well before requiring the cash to cover the anticipated shortfall at the backend of this year.
3. Increased production capacity due to upgrade to 3 Mtpa for the first five year (previously 2.5 Mtpa) and allowing for a minor output loss; there is no doubt this will affect the EPS as well as the increased in Dividend/share, I believe I am being conservative in my numbers with reference to PLS. (I hold).
4. At this point, I did not factor in a capital raise for the shortfall but as an additional loan (my preference) - but this can easily be paid off from the DSO revenue - it makes capital raise an un-attractive option.
5. Tony had already a number of times indicated; there is a possibility of going for a mid-stream product instead of LHM; which we will likely get a confirmation before end of this year - hence, there may be significant changes 2029 onwards.
- Forums
- ASX - By Stock
- Ann: Kathleen Valley Project Update
Hey@ChocolateTeapot, indeed I have revised my spreadsheet model...
-
-
- There are more pages in this discussion • 95 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add LTR (ASX) to my watchlist
|
|||||
Last
91.0¢ |
Change
-0.045(4.71%) |
Mkt cap ! $2.206B |
Open | High | Low | Value | Volume |
98.0¢ | 98.0¢ | 90.0¢ | $24.20M | 25.93M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 95000 | 90.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
91.0¢ | 10995 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 95000 | 0.905 |
58 | 891353 | 0.900 |
13 | 779509 | 0.895 |
29 | 500252 | 0.890 |
10 | 241915 | 0.885 |
Price($) | Vol. | No. |
---|---|---|
0.910 | 10995 | 2 |
0.915 | 41878 | 3 |
0.920 | 63243 | 7 |
0.925 | 10055 | 1 |
0.930 | 37709 | 6 |
Last trade - 16.10pm 03/07/2024 (20 minute delay) ? |
Featured News
LTR (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online